T1	Participants 121 173	patients with senile dementia of the Alzheimer type.
T2	Participants 863 923	patients with mild to moderate probable Alzheimer's disease.
T3	Participants 924 1009	A total of 204 patients with probable Alzheimer's disease were included in the study.
T4	Participants 1010 1215	Of these, 136 patients were eligible for the according-to-protocol analysis of efficacy, 167 subjects for the intention-to-treat analysis of efficacy, and 181 patients were included in the safety analysis.
T5	Participants 1478 1492	placebo group.
